### HeartBeam’s Innovative AI Advancements in Cardiac Monitoring
**SANTA CLARA, Calif., September 08, 2025** — HeartBeam, Inc. (NASDAQ: BEAT), a pioneering medical technology company, recently showcased groundbreaking study data at HRX Live 2025 that highlights their advancements in cardiac care. The company is redefining how we detect and monitor critical cardiac conditions, focusing on providing personalized insights through innovative technology.
### Key Findings from the Study
Dr. Joshua Lampert, a Cardiac Electrophysiologist and Medical Director of Machine Learning at Mount Sinai Heart, presented the significant findings of a comparative study involving HeartBeam’s deep learning algorithms. The study showed no significant differences in the detection rates of atrial fibrillation, atrial flutter, and sinus rhythm when analyzing ECG recordings from the HeartBeam System compared to standard 12-lead ECGs. This is crucial as it establishes the reliability of new technologies alongside traditional methods.
### Study Methodology
The study involved ECG recordings from 201 patients, utilizing both the HeartBeam device—which captures heart signals from three directions—and a standard 12-lead ECG. Deep learning algorithms developed from over 10,000 standard recordings were applied to both sets of data, which were then assessed against diagnoses from a panel of three electrophysiologists. This rigorous methodology enhances the credibility of the results.
### Performance Metrics
The results were impressive:
– **Accuracy Measures**: There were no significant differences in accuracy between the HeartBeam recordings and the standard 12-lead group. Specifically, the metrics showed:
– **131 sinus rhythm diagnoses**
– **57 atrial fibrillation diagnoses**
– **13 atrial flutter diagnoses**
– **High Detection Rates**: The algorithms achieved a detection accuracy of 94.5% for HeartBeam, compared to 95.5% for the standard 12-lead ECG. These results emphasize the capability of HeartBeam’s technology to match established standards in the field.
### Implications for Patient Care
Rob Eno, CEO of HeartBeam, remarked on the importance of these findings, noting that they represent a major leap in making advanced cardiac monitoring more accessible and user-friendly. The equivalent performance of the HeartBeam device—compact enough to fit in a wallet—alongside traditional ECG systems presents exciting prospects for patient care, particularly in environments where comprehensive 12-lead ECGs may not be feasible.
### Future Prospects and FDA Submissions
HeartBeam’s deep learning algorithms, which include insights from this significant study, are set to play a critical role in future FDA submissions aimed at expanding their product offerings. The company is dedicated to enhancing the capabilities of its technology, ensuring it meets the rigorous standards required for clinical adoption.
### About HeartBeam, Inc.
HeartBeam is revolutionizing the cardiac health landscape by developing the first-ever cable-free device designed to gather ECG signals in a 3D format. This innovation allows for portable monitoring of heart health trends and acute conditions outside traditional medical settings. The technology has already achieved FDA clearance for arrhythmia assessment and is under review for its 12-lead ECG synthesis software.
Those interested in learning more about HeartBeam can visit their [official website](https://www.heartbeam.com).
### Contact Information
For further inquiries, HeartBeam’s Investor Relations contact is Chris Tyson, Executive Vice President at MZ North America, reachable directly at 949-491-8235.
HeartBeam’s advancements in technology and ongoing commitment to improving cardiac care clearly signal a transformative shift in how heart health is monitored and managed.